Evidence map›Paper›PMID 42069746›Full record

ArticleNPJ vaccines2026

High affinity is insufficient for strong B cell activation by HIV broadly neutralising antibodies.

Chloe Rees-Spear, Olivia Payne, Emma Touizer, Alan Kennedy, Luke Muir, Peter Thomas, Alyssa Thomas DeCruz, Rachel A McKendry, Leo Swadling, Marit J van Gils and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chloe Rees-SpearInstitute for Immunity and Transplantation, UCL, London, UK.
Olivia PayneInstitute for Immunity and Transplantation, UCL, London, UK.
Emma TouizerInstitute for Immunity and Transplantation, UCL, London, UK.
Alan KennedyInstitute for Immunity and Transplantation, UCL, London, UK.
Luke MuirInstitute for Immunity and Transplantation, UCL, London, UK.
Peter ThomasInstitute for Immunity and Transplantation, UCL, London, UK.
Alyssa Thomas DeCruzLondon Centre for Nanotechnology, UCL, London, UK.
Rachel A McKendryLondon Centre for Nanotechnology, UCL, London, UK.
Leo SwadlingInstitute for Immunity and Transplantation, UCL, London, UK.
Marit J van GilsUMC, Amsterdam, the Netherlands.
James E VossThe Scripps Research Institute, La Jolla, CA, USA.
Laura E McCoyInstitute for Immunity and Transplantation, UCL, London, UK. l.mccoy@ucl.ac.uk.

Funding

Biotechnology and Biological Sciences Research Council BB/M009513/1EPSRC Centre for Doctoral Training in Technology Enhanced Chemical Synthesis EP/K031953/1EPSRC IRC in Agile Early Warning Sensing Systems in Infectious Diseases and Antimicrobial Resistance EP/R00529X/1Horizon 2020 Framework Programme 757601HORIZON EUROPE European Research Council 757601Medical Research Council MR/N013867/1Medical Research Council MR/R008698/1
6 · The paper itself

Abstract

HIV broadly neutralizing antibodies (bnAbs) have been widely studied, and inducing a robust broadly neutralizing response remains a goal for many human vaccine studies. Much research focusses on creating higher affinity antigens to target bnAb precursors, however this ignores the role of non-neutralisers that are known to dominate HIV-specific responses. Furthermore, any effective vaccine will likely need to induce multiple bnAbs. Here, we question whether the previously postulated affinity ceiling of 10

Identifiers

PMID42069746
PMCPMC13342595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.